Abstract
Fixed dose combinations of Pantoprazole and Tetracycline (PT) have a wider range of susceptibility than any one of these two drugs individually. The present study was carried out to determine the Minimum Inhibitory Concentration (MIC) and Time kill curve of Pantoprazole, Tetracycline and a fixed dose combination of these two drugs in four groups (HP-B1, HP-B2, HP-B3, HP-B4) of Helicobacter pylori (H. pylori) bacteria. The MIC were found to be 0.03125 mg/l, 0.03125 mg/l, 0.03125 mg/l, and 0.0625 mg/l for PT, 32mg/l, 64mg/l, 32mg/l, 64mg/l, respectively, for Pantoprazole and 0.125 mg/l, 0.125mg/l, 0.125mg/l, and 0.25mg/l for tetracycline, respectively, in the different groups . In all H. pylori groups studied, the time-kill curve analysis demonstrated maximum bacterial killing at 4 hours with PT having the most pronounced effect. From the present findings it can be concluded that a fixed dose combination of pantoprazole and tetracycline has better efficacy and more bacterial inhibiting properties than Pantoprazole or Tetracycline alone.
Keywords: Minimum inhibitory concentration, time kill curve, fixed dose combination, pantoprazole, tetracycline
Current Drug Therapy
Title: Comparative In Vitro Antimicrobial Activity of Pantoprazole, Tetracycline and a Fixed Dose Combination in Helicobacter pylori Infection
Volume: 4 Issue: 2
Author(s): Dharmendra Rai, Vivek Kumar Dwivedi, Manu Chaudhary, Sanjay Mohan Shrivastava, Praveen Rishi and Pramod Kumar Pandey
Affiliation:
Keywords: Minimum inhibitory concentration, time kill curve, fixed dose combination, pantoprazole, tetracycline
Abstract: Fixed dose combinations of Pantoprazole and Tetracycline (PT) have a wider range of susceptibility than any one of these two drugs individually. The present study was carried out to determine the Minimum Inhibitory Concentration (MIC) and Time kill curve of Pantoprazole, Tetracycline and a fixed dose combination of these two drugs in four groups (HP-B1, HP-B2, HP-B3, HP-B4) of Helicobacter pylori (H. pylori) bacteria. The MIC were found to be 0.03125 mg/l, 0.03125 mg/l, 0.03125 mg/l, and 0.0625 mg/l for PT, 32mg/l, 64mg/l, 32mg/l, 64mg/l, respectively, for Pantoprazole and 0.125 mg/l, 0.125mg/l, 0.125mg/l, and 0.25mg/l for tetracycline, respectively, in the different groups . In all H. pylori groups studied, the time-kill curve analysis demonstrated maximum bacterial killing at 4 hours with PT having the most pronounced effect. From the present findings it can be concluded that a fixed dose combination of pantoprazole and tetracycline has better efficacy and more bacterial inhibiting properties than Pantoprazole or Tetracycline alone.
Export Options
About this article
Cite this article as:
Rai Dharmendra, Dwivedi Kumar Vivek, Chaudhary Manu, Shrivastava Mohan Sanjay, Rishi Praveen and Pandey Kumar Pramod, Comparative In Vitro Antimicrobial Activity of Pantoprazole, Tetracycline and a Fixed Dose Combination in Helicobacter pylori Infection, Current Drug Therapy 2009; 4 (2) . https://dx.doi.org/10.2174/157488509788185196
DOI https://dx.doi.org/10.2174/157488509788185196 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular Therapy of Lysosomal Storage Disorders: Current Status and Future Prospects
Current Pediatric Reviews An Update on JAK Inhibitors
Current Medicinal Chemistry Ex Vivo Gene Therapy and Vision
Current Gene Therapy The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design Applications of Molecular Imaging in Drug Discovery and Development Process
Current Pharmaceutical Biotechnology Atopic Dermatitis in the Elderly
Inflammation & Allergy - Drug Targets (Discontinued) Cellular Signaling in Cartilage Tissue Engineering
Current Signal Transduction Therapy Fertility Preservation in Women After the Cancer
Current Pharmaceutical Design Cilostazol as a Unique Antithrombotic Agent
Current Pharmaceutical Design Natural Product Gossypol and its Derivatives in Precision Cancer Medicine
Current Medicinal Chemistry Baseline Levels of Interleukine-6, Tumor-Necrosis Factor-Alpha and C-Reactive Protein in Treatment Naive Human Immunodeficiency Virus Infected Patients-A Study from a Tertiary-Care Hospital in Eastern India
Current Biomarkers (Discontinued) LncRNAs as Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy
Current Cancer Drug Targets The PI3K/AKT/mTOR-Signal Transduction Pathway as Drug Target in Triple-Negative Breast Cancer
Clinical Cancer Drugs Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) Cancer Stem Cells and Therapeutic Perspectives
Current Medicinal Chemistry Molecularly Guided Therapy of Neuroblastoma: A Review of Different Approaches
Current Pharmaceutical Design CBP-dependent Wnt/β-catenin signaling is crucial in regulation of MDR1 transcription
Current Cancer Drug Targets Dendritic Cell-Based Immunotherapy in Thyroid Malignancies
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Changes in Glutathione, Oxidative Stress and Mitochondrial Membrane Potential in Apoptosis Involving the Anticancer Activity of Cantharidin Isolated from Redheaded Blister Beetles, Epicauta hirticornis
Anti-Cancer Agents in Medicinal Chemistry Depleted Uranium and Human Health
Current Medicinal Chemistry